Neisseria meningitidis compositions and methods thereof

US9822150B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Annaliesa Sybil Anderson · Upper Saddle River, US
• Rasappa Arumugham · Princeton, US
• John Erwin Farley · Rochester, US
• Leah Diane Fletcher · Richmond, US
• Shannon Lea Harris · Nanuet, US
• Kathrin Ute Jansen · Doylestown, US
• Thomas Richard Jones · New City, US
• Lakshmi Khandke · Nanuet, US
• Bounthon Loun · Athens, US
• John Lance Perez · Doylestown, US
• Gary W. Zlotnick · New Windsor, US

Key dates

• Filing date: Aug 27, 2014
• Grant date: Nov 21, 2017
• Expiry date: Aug 27, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.